60725-19-1

Basic information

• Product Name: Benzeneacetic acid, a-[(Methoxycarbonyl)aMino]-, (S)-
• Synonyms: Benzeneacetic acid, a-[(Methoxycarbonyl)aMino]-, (S)-;(S)-2-((Methoxycarbonyl)amino)-2-phenylacetic acid;(S)-2-(methoxycarbonylamino)-2-phenyl;(S)-2-(methoxycarbonylamino)-3-phenylacetic acid
• CAS NO: 60725-19-1
• Molecular Formula: C₁₀H₁₁NO₄
• Molecular Weight: 209.19864
• Mol File: 60725-19-1.mol
• Article Data: 18

Chemical Properties

• Appearance: /
• Density: 1.283
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: Benzeneacetic acid, a-[(Methoxycarbonyl)aMino]-, (S)-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzeneacetic acid, a-[(Methoxycarbonyl)aMino]-, (S)-(60725-19-1)
• EPA Substance Registry System: Benzeneacetic acid, a-[(Methoxycarbonyl)aMino]-, (S)-(60725-19-1)

Safety Data

• Hazardous Substances Data: 60725-19-1(Hazardous Substances Data)

Usage

General Description

Benzeneacetic acid, a-[(methoxycarbonyl)amino]-, (S)-, also known as S-ibuprofen, is a nonsteroidal anti-inflammatory drug (NSAID) that is commonly used to relieve pain, reduce fever, and decrease inflammation. It works by inhibiting the production of certain chemicals in the body that cause pain and inflammation. S-ibuprofen is available in various forms, including tablets, capsules, and oral suspension. It is often used to treat conditions such as arthritis, muscle aches, headaches, menstrual cramps, and minor injuries. While generally considered safe and effective when used as directed, S-ibuprofen can cause side effects such as stomach upset, heartburn, and dizziness, and should not be used in certain medical conditions or in combination with certain medications.

Upstream product

• 5817-70-9 methyl N-benzylcarbamate 
• 21116-73-4 N-Benzyl-N-trimethylsilyl-carbamidsaeure-methylester 
• 53934-78-4 (S)-2-amino-2-phenylacetic acid tert-butyl ester 
• 2935-35-5 (S)-2-phenylglycine 
• 79-22-1 methyl chloroformate 

Downstream Products

• 1419384-95-4 C₅₃H₅₆N₈O₆ 
• 1612854-34-8 C₅₈H₅₈N₈O₇ 
• 1613056-66-8 C₂₃H₂₂BrN₃O₄ 
• 1613056-68-0 methyl ((S)-2-((S)-2-(5-(4-bromophenyl)-1H-imidazol-2-yl)pyrrolidin-1-yl)-2-oxo-1-phenylethyl)carbamate 
• 1560642-41-2 C₂₇H₃₃BN₄O₅ 
• 1208007-66-2 methyl ((1R)-2-((2S)-2-(4-(5-(2-((2S)-1-((2R)-2-((methoxycarbonyl)amino)-2-phenylacetyl)-2-pyrrolidinyl)-1H-benzimidazol-5-yl)-1,3-oxazol-2-yl)-1H-benzimidazol-2-yl)-1-pyrrolidinyl)-2-oxo-1-phenylethyl)carbamate 
• 115199-84-3 ICI 199441 hydrochloride 

Relevant articles and documents

Redesigning of the cap conformation and symmetry of the diphenylethyne core to yield highly potent pan-genotypic NS5A inhibitors with high potency and high resistance barrier

Herein, we report the discovery of several NS5A inhibitors with potency against HCV genotype 1b in the picomolar range. Compounds (15, 33) were of extremely high potency against HCV genotype 1b (EC50 ≈ 1 pM), improved activity against genotype 3a (GT 3a) and good metabolic stability. We studied the impact of changing the cap conformation relative to the diphenylethyne core and/or compound symmetry on both potency and metabolic stability. The analogs obtained exhibited improved potency against HCV genotypes 1a, 1b, 3a and 4a compared to the clinically approved candidate daclatasvir with EC50 values in the low picomolar range and SI50s > 7 orders of magnitude. Compound 15, a symmetrically m-, m’-substituted diphenyl ethyne analog, was 150-fold more potent than daclatasvir against GT 3a, while compound 33, an asymmetrically m-, p-substituted diphenyl ethyne analog, was 35-fold more potent than daclatasvir against GT 3a. In addition, compound 15 exhibited a higher resistance barrier than daclatasvir against genotype 1b.

Symmetric benzidine derivatives as anti-HCV agents: Insight into the nature, stereochemistry of the capping amino acid and the size of the terminal capping carbamates

Novel symmetric molecules, bearing a benzidine prolinamide core, two terminal carbamate caps of variable sizes and nature, including natural and unnatural amino acids were developed. Several terminal N-carbamate substituents of the core structure, ranging from linear methyl, ethyl and butyl groups to branching isobutyl group; and an aromatic substituent were also synthesized. Series 1 has hydrophobic AA residues, namely S and R phenylglycine and a terminal carbamate capping group, whereas Series 2 bears sulphur containing amino acids, specifically S and R methionine and the natural R methylcysteine. The novel compounds were tested for their inhibitory activity (EC50) and their cytotoxicity (CC50), using an HCV 1b (Con1) reporter replicon cell line. Compound 4 with the unnatural capping residue, bearing D-Phenylglycine amino acid residue and N-isobutyloxycarbonyl capping group, was the most active within the two series, with EC50 = 0.0067 nM. Moreover, it showed high SI50 > 14788524 and was not cytotoxic at the highest tested concentration (100 μΜ), indicating its safety profile. Compound 4 also inhibited HCV genotypes 2a, 3a and 4a. Compared to the clinically approved NS5A inhibitor Daclatasvir, compound 4 shows higher activity against genotypes 1b and 3a, as well as improved safety profile.

Diphenyl sulfate derivatives or pharmaceutically acceptable salts thereof, preparation method thereof and pharmaceutical composition for use in preventing or treating hepatitis C virus related diseases

The present invention relates to a diphenyl sulfate derivative or a pharmaceutically acceptable salt thereof, a production method thereof, and a pharmaceutical composition for preventing or treating hepatitis C virus-associated diseases containing the same as an active ingredient. According to the present invention, the diphenyl sulfate derivative excellently inhibits infection by hepatitis C virus and replication of hepatitis C virus, and thus can be useful as pharmaceutical compositions for preventing or treating liver diseases such as hepatocellular cancer, cirrhosis, chronic hepatitis C, and acute hepatitis C caused by hepatitis C virus.COPYRIGHT KIPO 2017